Member Info for Notpotalot

Towards the end of the Dec webinar, Mark stated, “the runway extends into H2 but looking to supplement that with R&D tax credits, Inaphaea revenue and grant applications outstanding”. He then set out 6 clear objectives and milestones for 2026:

• Additional Inaphaea customers – revenue generation and lab breakeven. Multiple grant opportunities.

• 3k screen purposing selection & patent filings – partner primary asset. Progress top 10 low-hanging fruit rapidly.

• VAL201 validation & patent filings – Blue Ribbon Bio external investment –either grant or venture capital funding. Looking to dilute asset, not Val Plc.

• CytoLytix formulation selection, safety testing & immune engagement. Ongoing discussions with big pharma. Looking at opportunities in vet mkt – partner &/or another grant to progress into IND studies.

• Pipeline expansion – sign 2 preclinical evaluation agreements & one SPV. 2 discussions at very mature stages.

• Decision points on current evaluations – StingRay, Dundee & Altus

Yesterday’s Inaphaea update was laid out with specific sub-headings:

• Pipeline expansion - sign 2 preclinical evaluation agreements and 1 SPV

• Cytolytix formulation selection, safety testing and immune engagement - partner and/or grant

• VAL201 2.0 validation and patent filings - Blue Ribbon Bio external investment

Look at the wording - this is not coincidence - the CEO is making a very deliberate point. Last year, Mark under-estimated the timeline to Inaphaea breakeven. This year, he intends to make no such misstep. Consider where Val PLC will be by December if he maintains this early trajectory: Inaphaea breakeven, top Val/Dom asset partnered, Blue Ribbon/201 grant or VC funded & CLX partnered or grant funded into IND stage. Not only would this progress assets faster, it would reduce PLC outgoings significantly, leading to a much smaller runway requirement.

The last two objectives have major potential too. If the remaining evaluation is on a par with McGill/IRICoR (global players, later stage asset, early monetisation potential), it could be another significant addition to the pipeline. Val is also approaching decision time on 3 current evaluations: StingRay, Dundee & Altus. Early in his tenure, Mark terminated the Barcelona evaluation - the guidelines are clear, promising or not, an evaluation will be ended if not compatible with his early monetisation tenet. All 3 evaluations have potential in their respect fields but it is noticeable that in the webinar Mark only commented on one, the Dundee project – which he said was “progressing well”.

Yesterday, without prompt, Mark reminded holders of his 2026 objectives and his intention to meet the milestones or be held to account. This is a CEO publicly setting the bar and committing to delivery – he will remind holders as he ticks them off, one by one. This makes Val one of the hottest prospects AIM has seen in years.

GLA, DYOR

Sounds very much like sour grapes, Agent Rat.

This is the Science and economics class. History lessons are down the corridor. I’ve seated you next to Porky so you can console each other.

By the way, today’s grants were petty cash compared to what’s lined-up! 😆

Gee, Porky, chill. Only 6 more days until your promised placing. I guess it’s squeaky b*m time for you. 🤣🤣🤣

Just a quick reminder of your guarantees:

18 Dec, 16.01 – “before the runway runs out end of March”

19 Dec, 1.52 - “Before the end of March ME will need to get the next placing away”

20 Dec, 23.49 - “End of March before Tax year end”

23 Dec, 13.22 - “NOT enough cash ….beyond the end of March”

13 Jan, 15.39 - “Only thing that will bring hard cash…. in the next 8 weeks will be placing”

24 Jan, 14.03 - “ ….discounted placing, can't be far off now, a few weeks at most”

11 Feb, 17.06 - “March placing 650m new shares”

Tick-tock, CEO Mark has confirmed a runway into H2 minimum, EXCLUDING Inaphaea income (update imminent), grants (with several pending), R&D tax credits (at least one month’s extension alone), venture capital partnering (dilute assets, not Val PLC) and warrant income (£1.8m available from the 0.5p issue alone).

Let’s lock in 31 March as the date for Professor Porky’s quarterly review. 🤡

Incidentally, the resident historians keep claiming no significant RNS has landed, yet the SP is currently 35% higher than on 21st Nov, even after recent trading. If that’s the baseline BEFORE news, imagine the reaction following it!

GLA

Credit where it’s due, Nick - you identified Val’s potential a while back. Your last 97 (ninety-seven) consecutive posts have ALL been on Val. Every last one.

For a trader who prides himself on his ability to spot AIM multi-baggers early, it says everything about where you see the next banker.

Cheers 👍🤣

Fans used to buy a football programme before going into the match to catch up on team news, club developments and what’s coming next. Scientific publications are the Biotech equivalent. They’re how the industry checks who are the up-and-coming players, who to watch, and which teams can play at a higher level.

Peer reviewed papers, invited editorials and an AACR slot are the signals that tell pharma, investors and grant bodies: this company has the qualities we need. Without these markers, no asset - whether it’s a digital avatar platform, or VAL201 - gets recognised by the key players who make partnerships and funding happen.

DYOR

The only reason the Valirx SP is not already nudging warrant territory is the persistent runway doubts being pushed by the uninvested with agendas. Yes, the share has historically been a poor investment for many - but not for all. As with every lowcap, we have a few mischief makers. However, the chief protagonist is Nick S (Viera), self-proclaimed trader with a decent X following. Nick has made multiple killings on Val over the years and now posts exclusively on this share - 96 consecutive LSE posts and counting. I’m betting that number will jump when he reads this. 🤣

So, what changed to transform the company?

Mark E happened!

Since taking over as CEO 19 months ago, Mark has completely revitalised Val. A commercially savvy scientist, he quickly identified what needed fixing. He inherited a weak financial situation and twice asked shareholders to back his vision. However, unlike previous management, he backed his conviction with his own cash. He now owns 8% of the company.

Rather than splashing out on expensive cutting-edge AI modelling equipment, Mark did what experienced operators do: he partnered. By collaborating with UK and international groups, he massively expanded Val’s capabilities, accelerated PDC screening, reduced costs, and positioned Val at the front of the queue for grant eligibility by reducing reliance on animal testing.

Val now has 4 SPVs, three of which are being fast-tracked for partnering/venture capital. The science is well covered elsewhere, but few SME biopharmas can match the breadth of assets Val has in its portfolio. Mark recently confirmed the company has 40 separate projects running in its Inaphaea labs: a scale the old Val could only dream of.

When the cash runway extends rather than contracts over the coming months, the market will finally recognise that Val is a company reborn. Once the SP pushes past 0.6p, the 0.5p warrants will begin to be exercised, potentially putting another £1.8m into Val’s coffers.

That aside ….and back to our trader friend. Just look at where Nick S is spending 100% of his time. It is clear where he sees the next multi-bagger. You couldn’t get a better endorsement.

Cheers Nick! 😜

I could add a few more to Pater’s Q&As.

Q1 - Why does Nick (Viera) need 96 consecutive Val posts to tell us how bad Val is? 🤔

A1 - Nick is simply a ruthless trader. It doesn’t take a genius to see he is desperate for the bigger holders to offload.

Q2 - What embittered Porky so much to waste 4 years of his life and over 6000 posts slagging off Val? 🤔

A2 - He was Val’s biggest ramper, sold the lot to put into 4D which then folded. Easier to blame Val than his own stupidity.

Q3 - Why do others spend hours posting on a share they aren’t invested in? 🤔

A3 - Mischief makers, boredom, attention-seeking, social issues, shorting, or annoyed at historical Val losses

When the grant RNS lands, it’s like musical chairs. The music stops and it’s the ones already in their seats who will win — not the ones still circling the room.

GLA

Rat – What’s with the “if”. I guarantee be I’ll here in 13 days, completely vindicated, to call out Porky’s scaremongering purely for devilment. Having spent 4 years blaming Val for his own stupidity going all-in to a joke company (4D), he cannot accept Val has transformed and will still be slagging off Val as they carry him off in a straightjacket. 😖

However, as the clock ticks down he will inevitably move the goalposts back and deny the end of March claims. No matter, all copied and pasted ready for his denials.

Porky gives up!

It’s clear Porky has completely abandoned any attempt at picking winners. Having finally accepted how consistently wrong his ‘surefires’ have been, every post now focuses on predicting the downfall of various shares. There isn’t a single effort to highlight companies he genuinely believes will succeed. And the funniest part? If he’d shorted the shares he once ramped like a man possessed, he’d have actually made a killing. He could have sold £1m worth of 4D and HARL at the time, banked the proceeds and later bought them back for less than a penny. 🤔 😭

Anyway, only 13 days till Porky’s absolute deadline for another placing. That’s until he accepts it ain’t happening so moves his deadline back 6 weeks, then another 6 weeks, then…etc. 😁

Glad you liked the post, Nick. 😀

While I’m not nitpicking, a few corrections to your own post.

Firstly, I am not unemotional to my losses. I haven’t sold any! For future reference, you are only susceptible to losses when you capitalise them. With an average below the previous 0.65p placing, I am more than happy with my position. Buying below 0.25p does wonders to an average.

Secondly, I don’t work for Val. I have researched the company I’m invested in, as all investors should.

Thirdly, CEO Mark has confirmed the runway is into H2, before grants, Inaphaea income, R&D tax credits and exercised warrants, so “cash balances are approaching zero” is completely untrue, tho’ I get why the reality would not fit in with your agenda.

Finally, maybe try verifying facts before posting – it’s easy and only involves checking recent RNSs. Mark currently holds 59746187, 1m were bought on 4th March, 36m in the 0.25p placing, 20769230 in the 0.65p placing and 1,976,957were held at the time of his app’t as CEO. To say “much of Mark’s stock was purchased above 30p” is totally untrue. Anything below the threshold isn’t disclosed, so no one can claim he bought ‘mostly above 30p. The absolute most he could have is 3.3% of his current total, and likely averaged down at some point prior to his appointment.

I actually find it reassuring to believe the CEO might have an average higher than my own, particularly with Mark buying so heavily only last Nov.

Like all your ‘Ultras’, never let a few facts get in the way of a good deramp!

Have a good evening.

A late win, but if we apply the Nick Ultras’ logic, the Gunners will never win the league again. They haven’t lifted the trophy since Vieira in 2004, so even if they signed Messi, Mbappé, Dembélé, Yamal, Haaland and Bellingham, it still wouldn’t make any difference - would it?

Meanwhile, over at Valirx FC, experienced manager Marcus Ecclestonni believes in the club so much he has bought 8%. He’s built a compact but highly experienced coaching staff around him, all aligned with his ambition to take Val to the very top.

On the pitch, Marcus has assembled a genuinely top-class squad and because he recognises the importance of flexible playing patterns has brought in players with different strengths: CLX provides the driving force, repurposing brings the range, veterinary adds versatility, immunotherapy supplies defensive resilience, clickmers deliver creativity and behind them, a bench full of emerging talent.

His abilities in the transfer market were highlighted when he sold defender VAL401 for a lucrative £16m plus royalties to Ambrose FC, and then pulled off the masterstroke of getting him loaned back with Ambrose even paying Val for the privilege of letting them develop their own player. Mind you, Mr Ecclestonni’s talent for shrewd trading was highlighted while at Volition FC when he sold promising teenager Nu.Q for $28m.

Off the pitch, the commercial interest is heating up. Emirates, Etihad Airways, Standard Chartered, and Adidas (or biopharma equivalents) are all vying to get their names on the shirt. Val FC has genuine “feeder clubs” through its collaborations with Omios, Voxcell, TwinEdge, McGill, IRICoR and a whole network of others feeding talent and opportunities into the system. Attendances have improved at Val Park, and the gate receipts have risen 43% over the last 16 weeks.

Even the governing body seems to recognise Val FC is building something special. They’ve modernised the rulebook to encourage clubs that play the right way: NAM-focused. Grants, incentives and new frameworks are all being shaped to reward Val FC’s forward-thinking approach.

Ten years ago, an exciting Leicester side walked the prem, ironically keeping your team off the top. Now they look destined for another relegation. That’s what happens when the infrastructure isn’t in place. Val FC are being built for sustained dominance, not the quick wins that some competitors chase.

If Gunners fans can believe in a title challenge after 25 years without winning it, surely Val supporters are entitled to the same optimism now that they’ve actually assembled the strongest squad and structure they’ve ever had.

COYV, GLA

“It looks like the big push has started” (Rat – today) 😂

The reality? Only 38 of the last 100 posts have been neutral or Val-positive. 62% have been attempts to deramp the share and supress the SP. The desperation is understandable with so much news due over the coming months.

It is noticeable that most of the negative posts focus on 2 tired angles: Val’s history and lies about the runway. Mark has never shied away from the company’s past failings, indeed as a long-term holder, he too was considerably underwater on his appointment. His stated objective was simple: to ensure the company becomes self-financing and then profitable. 18 months down the line, he is on the cusp of making that reality.

We then come to runway nonsense. Porky claims Val only has 18 days left until the next placing. What a load of tosh. The CEO has confirmed a runway into H2 and that’s BEFORE grants, Inaphaea income, tax credits or exercised warrants. Furthermore, not a single recent statement from Mark concedes any placing at all. Every placing reference originates from the same handful of uninvested posters who repeat it daily in the hope it sticks.

The truth is simple: the derampers are running out of road, and they know it. Val is strengthening, news is building, and the fundamentals are moving in one direction. The noise will fade — the progress won’t.

AIMO, DYOR

It only takes 30 seconds to confirm. Legendary trader🤔 Nick Slater’s last 89 (eighty-nine) consecutive posts have ALL been on Valirx to tell us just how crap we are. Let that sink in!

Thanks for the ringing endorsement, Nick, but it wasn’t needed. We already knew - Val is probably the best prospect on the AIM. Great to know we have your support though!

Pleasant dreams. 🤣🤣🤣🤣🤣

Gee man, so many negative vibes. What’s with the cosmic gloom every time Val’s SP floats upwards? You uninvested doom groovers must be totally spaced out, trying to hold back the sunshine with all that rain. More rises are coming, cats, so stash those umbrellas.

Pretty soon, Mark babe will be bringing in the dough and you lucky dudes who are in the groove will be ridin’ high, while rain riders will be soaked in their own bad karma.

Peace, love… and look for the 🌈, you beautiful people. 🌞🤣🌞🤣

I guess it depends on your perspective, Nick. If you desperately want the SP to drop you would put the “director buying is a danger signal” spin on today’s TR1. 🤣

Holders would say that if the CEO increases to 8% of the shares in issue, he is very confident in news due over the coming months. It’s a pretty crap market with the Middle East situation so to buy more yesterday has to be viewed as positive. Directors rarely buy into weakness unless they believe the medium-term outlook is stronger than the market is pricing.

Remember, with a runway into H2 minimum, the only ones panicking are the uninvested who have 4 weeks left before months of lies and scaremongering are exposed.

GLA, DYOR

The 1m shares bought yesterday aren’t the real signal — it’s the 58.7m accumulated beforehand that shows the true direction of travel.

Trying to spin a director buy as a negative says more about the desperation of the uninvested few than it does about the company.

Porky has 27 days left for his “placing incoming” prediction to materialise, and the clock is ticking. In the meantime, the market is offering prices that LT holders, even the CEO, are happy to take advantage of.

Porky, already in my diary for us to catch up on 31st March. You are in for a rude awakening over the coming months. 4 years of slagging off Val, yet here it still is, better positioned than ever to succeed.

Any news on 4D or HARL’s reinstatements yet? No, thought not. Such a shame you suckered so many into those joke companies. No wonder you post into the night, I guess it’s the guilt.

Anyway, don’t forget, 31st March. Bring tissues. 😭😭😭

Hi Nick, apparently you consider Val a bad investment – 83 consecutive posts on this forum might suggest otherwise. LOL

I really want to take you seriously, but when you suggest Porky for the Board, come on – has to be a wind-up. Did you honestly not foresee the 4D disaster, or HARL. Numerous posters tried to warn Porky, but he knew better and ramped them both to the bitter end, being very abusive to those telling him to be careful. And you honestly think he is Board material? 🤣🤣🤣

Val was doomed 3 years ago according to Porky, yet unlike his companies in administration, here we are: new CEO as main shareholder, streamlined-team, multiple routes to monetisation, cash in the bank (afraid so!), costs significantly cut, partnering deals being lined up, grants pending, VC negotiations underway, etc. Yet your obsession is with an ex rival who you have put on fantasy wages – gosh, he must have really shown you up! 🤣

Every share has ups and down – Val is strolling up Everest! No wonder you can’t stay away! Anyway, enjoy the next few months, I will. 👍🙂😁🤣

I could be wrong, but to any reasonable observer it is seems clear PP is comfortable with how things are progressing. He’s not exactly missing much by ignoring the same handful of recycled posts. 😂

Mark E certainly won’t be concerned either. With months of runway ahead at a bare minimum, a few uninvested historians aren’t going to influence his schedule or priorities.

The company has been executing a long-term plan for over a year, and the prevailing SP is not a factor for consideration. The runway gives them time; the pipeline gives numerous options; and the upcoming milestones, several opportunities to put Val comfortably into warrant territory. Meanwhile, the naysayers have about four weeks before their scaremongering is exposed for what it is. No wonder the panic is creeping in.

Although without being deep into the science, it does seem long-term stability and growth are factors behind all of Mark’s decisions since his appointment. There also appears to be a certain logic to the flow: Advisory Board set up to identify new opportunities, Omios evaluation underway, CLX/oncovirus vet potential highlighted, Omios/Val 1-2-1 CEO meetings, veterinary SPV launched. It’s not unreasonable to consider, could this be the first CLX licence? It does seem logical.

Anyway, whichever side of the fence, come August the losers will be crying – commiserations, Porky and the girls! 😂 😂 😂

DYOR, GLA

Picture being a recognised trader with a decent reputation and following. You made your name picking up lowcap AIM companies and making a quick kill before the market cottons on. You have a reputation for being ruthless but successful, sourcing companies with low, unrealistic market caps. You buy in at the lows, build a position, reveal your ‘nugget’ to the market - and then offload for considerable gains.

Take a bow, Nick (Viera), who’s last 81 (eighty-one) LSE posts have ALL been on Val – and hardly complimentary. 🫢 Valirx is so bad that he needs to trash it 81 times on the trot - until suddenly it isn’t. When he has built his position, the world will hear of the goldmine HE has uncovered. How the CEO is a legend and the largest shareholder. How major pharma are circling to partner. He’ll talk of the numerous assets in play to give multiple shots on goal. And how many of his mates are holders (actually, very true … and still adding!).

As a trader, he is only interested in multi-bag potential, so will likely lock in a quick 300+% gain before again reminding us…. just how bad Val is! 😂